CP-T2 is a dual receptor agonist currently being investigated for metabolic regulation, glucose homeostasis, and body weight management research. It simultaneously activates the GLP-1 and GIP receptors, providing complementary effects on appetite regulation, insulin signaling, and metabolic function. As one of the most extensively studied incretin-based compounds, CP-T2 continues to demonstrate promising results across both clinical and preclinical research.
Metabolic Research
GLP-1 • GIP
Clinical & Preclinical
Weight Management
CP-T2 is a proprietary designation used by ChoicePeps for a research compound corresponding to tirzepatide, a next-generation dual receptor agonist that simultaneously activates the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual-pathway approach has generated significant scientific interest because it combines complementary mechanisms associated with appetite regulation, insulin secretion, and metabolic control into a single investigational molecule.
Unlike traditional GLP-1 receptor agonists that target only one incretin pathway, CP-T2 incorporates GIP receptor activity, allowing researchers to investigate its potential effects on insulin sensitivity, body weight regulation, and overall metabolic health. Preclinical and large-scale clinical studies have demonstrated substantial reductions in body weight together with meaningful improvements in glycemic control and several cardiometabolic biomarkers, making CP-T2 one of the most extensively studied investigational metabolic peptides currently under development.
Current research continues to explore CP-T2’s pharmacology, receptor signaling, long-term safety profile, and potential applications across obesity, type 2 diabetes, metabolic disease, and related areas of biomedical research. As with all compounds featured in the ChoicePeps Research Library, CP-T2 is presented for educational and scientific reference purposes only.
SURMOUNT-1 Phase III Trial Up To 22.5% Mean Body Weight Reduction Together With Significant Improvements In Cardiometabolic Risk Factors.
Review Of CP-T2 Clinical Performance Highlighting Improvements In Glycemic Control, Weight Reduction, And Overall Metabolic Health Across Multiple Clinical Studies.
Comprehensive Review Examining Dual GLP-1 And GIP Receptor Agonism And Its Role In Next-Generation Metabolic Disease Research.
Clinical Research Demonstrating Significant Improvements In Glycemic Control, Insulin Sensitivity, And Cardiometabolic Biomarkers With Tirzepatide Therapy.
Current preclinical and clinical research is investigating CP-T2 across several important areas of incretin biology, metabolic regulation, and cardiometabolic science.
CP-T2 is ChoicePeps’ proprietary designation for a research compound corresponding to tirzepatide, a dual incretin receptor agonist currently being investigated for metabolic regulation, glucose homeostasis, and body weight management. It simultaneously activates both the GLP-1 and GIP receptors, making it one of the most extensively studied investigational compounds in metabolic research.
Unlike traditional GLP-1 receptor agonists that activate only the GLP-1 receptor, CP-T2 also activates the GIP receptor. Researchers believe this dual receptor approach may provide complementary effects on insulin secretion, appetite regulation, glucose control, and body weight management, leading to enhanced metabolic outcomes compared with single-pathway therapies.
Dual incretin receptor agonists represent an important advancement in metabolic research because they target two complementary hormonal pathways involved in glucose regulation and energy balance. Current research is exploring how simultaneous GLP-1 and GIP receptor activation may improve insulin sensitivity, body weight reduction, and overall metabolic health.
CP-T2 has been evaluated in numerous large-scale clinical trials, including the SURPASS and SURMOUNT research programs. These studies have demonstrated significant improvements in glycemic control, body weight reduction, and multiple cardiometabolic biomarkers, making it one of the most thoroughly studied investigational metabolic compounds available today.
CP-T2 activates two receptors involved in metabolic regulation: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Together, these pathways help regulate insulin secretion, appetite, glucose metabolism, and overall energy balance in research models.
Has been approved by the U.S. Food and Drug Administration for specific medical indications under prescription use. However, the CP-T2 compound featured in the ChoicePeps Research Library is offered exclusively as a research material for laboratory and scientific investigation. It is not intended for human consumption or clinical use.
The information presented in the ChoicePeps Research Library is provided solely for educational and informational purposes. Content is compiled from publicly available scientific literature and is intended to summarize current areas of research involving investigational compounds.
The material presented on this page has not been evaluated by the U.S. Food and Drug Administration (FDA) and should not be interpreted as medical advice, treatment recommendations, or evidence of clinical efficacy. Scientific understanding continues to evolve as additional laboratory and clinical research becomes available.
ChoicePeps does not make claims regarding the diagnosis, treatment, cure, or prevention of any disease. Visitors are encouraged to consult original peer-reviewed publications when reviewing scientific findings.
